# Beam Therapeutics Inc.: Form 10-Q for the period ended Jun 30, 2021

- Company: [Beam Therapeutics Inc.](/companies/beam.md) (CIK 1745999)
- Form: 10-Q
- Filed: 2021-08-10
- Accepted by EDGAR: Aug 10, 2021, 07:46 ET
- Period: 2021-06-30
- Accession: 0000950170-21-001110
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1745999/000095017021001110/beam-20210630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1745999/000095017021001110/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-01 to 2021-06-30 | $6.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2021-01-01 to 2021-06-30 | $12.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2021-04-01 to 2021-06-30 | $45.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-01-01 to 2021-06-30 | $235.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | −$59.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-01 to 2021-06-30 | −$259.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2021-04-01 to 2021-06-30 | −$76.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-01-01 to 2021-06-30 | −$277.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-04-01 to 2021-06-30 | −$1.23 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-01-01 to 2021-06-30 | −$4.54 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-04-01 to 2021-06-30 | −$1.23 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-01-01 to 2021-06-30 | −$4.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-04-01 to 2021-06-30 | 62,210,239 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-01-01 to 2021-06-30 | 61,215,705 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | −$71.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-01-01 to 2021-06-30 | $27.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-06-30 | $212.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $678.0m | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $893.1m | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $128.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-06-30 | $344.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-06-30 | $548.6m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1745999/000095017021001110/beam-20210630.htm

Filed Aug 10, 2021.
Source: SEC EDGAR, the filing index for accession 0000950170-21-001110. Last ingested by Listed: Nov 14, 2026, 12:58 ET. No prices; not investment advice.
